Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Covington Represents Emergent BioSolutions in $270M Acquisition

Press Release August 9, 2018

Covington Represents Emergent BioSolutions in $270M Acquisition

August 9, 2018

WASHINGTON—Covington advised Emergent BioSolutions in its $270 million acquisition of PaxVax. PaxVax is majority owned by an affiliate of Cerberus Capital Management.

Emergent is a global life sciences company focusing on providing specialty products for civilian and military populations that address public health threats. PaxVax is a company focused on specialty vaccines that protect against existing and emerging infectious diseases.

The Covington team included Michael Riella, Catherine Dargan, and Joseph Gangitano (M&A); Denise Esposito and Allison Whelan (regulatory); Miranda Cole, James Dean, and James O'Connell (antitrust); Michael Francese (employment); Ansgar Simon and Daniel Luchsinger (tax); Amy Toro (life sciences); Heather Haberl (real estate); and Marie Lavalleye (intellectual property).

Related Professionals

Share links:

Share links:

Related Practices

Related Industries

Related Offices

Related Regions

Related News & Insights